Intra-Cellular Therapies
Manufacturing · New Jersey, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
135 Route 202/206 Ste 6, Bedminster, New...Phone Number
(888) 252-4824Revenue
$680.9 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Intra-Cellular Therapies
Founded in 2002, Intra-Cellular Therapies is a biopharmaceutical company that develops drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the CNS. Intra-Cellular Therapies is located in New York.Explore more
Intra-Cellular Therapies Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Intra-Cellular Therapies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Intra-Cellular Therapies has recently received funding, and reach out quickly before it becomes old news!
Check out if Intra-Cellular Therapies is spiking on competitors!
Earning: See what the market has to say on Intra-Cellular Therapies recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Intra-Cellular Therapies
Website visits: Recent activity has been detected on your website
Intra-Cellular Therapies, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Intra-Cellular Therapies had a recent Job posting/layoffs
Product Launch: Get notified when Intra-Cellular Therapies launches new products
Funding: Get notified immidiatlly once Intra-Cellular Therapies has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Intra-Cellular Therapies
Find 3 more new buyers
Compare Similar Companies to Intra-Cellular Therapies
Compare insights from companies similar to Intra-Cellular Therapies, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Intra-Cellular Therapies
$680.9M
501-1,000
Private
$1.1B
2002
SD
Suresh DurgamChief Medical Officer & Executive Vice President
$827.1M
501-1,000
Public
$2.5B
1998
QN
Quintus NgumahVice President, Clinical Development & Chief Marketing Officer, Cos To The
Company Profile Activity
Activity Insights
Intra-Cellular Therapies is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Intra-Cellular Therapies is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Intra-Cellular Therapies.
Intra-Cellular Therapies financials insights
Gather financial insights about Intra-Cellular Therapies, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Debt
$15.3M
Share Placement
$60M
2014
Stock Offering
$115.3M
2015
Stock Offering
$121.4M
Stock Offering
$327.4M
2017
Stock Offering
$141M
2020
Stock Offering
$295M
Intra-Cellular Therapies Tech Stack
A closer look at the technologies used by Intra-Cellular Therapies
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Left Company
Executive Move
Executive Moves, Left Company
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Intra-Cellular Therapies News & Media
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson Innovative Medicine. “At Johnson & Johnson, we are committed to transforming care for the millions of people worldwide living with neuropsychiatric and neurodegenerative disorders,” said Joaquin Duato, Chairman anITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) to Johnson & Johnson for $132.00 per share in cash is fair to Intra-Cellular shareholders. Halper Sadeh encourages Intra-Cellular shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigationIntra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results
Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million, representing a 51% increase over the same period in 2023
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Intra-Cellular Therapies
Sign Up For FreeTo access detailed company insights
Founded in 2002, Intra-Cellular Therapies is a biopharmaceutical company that develops drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the CNS. Intra-Cellular Therapies is located in New York.... Read More
